Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ICOTYDE (ICOTROKINRA) APPROVED BY FDA IN MARCH FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS, TRIGGERING A $50 MILLION MILESTONE PAYMENT; PROTAGONIST RECEIVES TIERED ROYALTIES OF 6% TO 10% AND IS ELIGIBLE FOR UP TO $580 MILLION IN FUTURE MILESTONE PAYMENTS RUSFERTIDE NDA ACCEPTED AND GRANTED PRIORITY REVIEW BY FDA, WITH A PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE IN THE THIRD QUARTER OF 2026 PROTAGONIST EXERCISED ITS RUSFERTIDE OPT-OUT RIGHT UNDER THE TAKEDA COLLABORATION ON APRIL 28, TRIGGERING A $200 MILLION OPT-OUT FEE PAYABLE TO THE COMPANY; ELIGIBLE FOR ADDITIONAL $200 MILLION OPT-OUT AND $75 MILLION MILESTONE PAYMENTS UPON NDA APPROVAL, SALES MILESTONES OF UP TO $775 MILLION AND WORLDWIDE ROYALTIES RANGING FROM 14% TO 29% PN-881 (ORAL IL-17 ANTAGONIST PEPTIDE) PHASE 1 STUDY COMPLETION BY MID-2026 AND PHASE 2 INITIATION ANTICIPATED BY YEAR-END; PN-477SC AND PN-477O (SC AND ORAL TRIPLE GLP/GIP/GICG AGONIST) PHASE 1 INITIATION EXPECTED IN MID-2026 AND Q1 2027, RESPECTIVELY CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $620 MILLION AS OF MARCH 31, 2026, ANTICIPATED TO PROVIDE CASH RUNWAY THROUGH AT LEAST 2028 NEWARK, CA / ACCESS NEWSWIRE / MAY 5, 2026 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE. "THE FIRST QUARTER OF 2026 MARKED A SERIES OF LANDMARK ACHIEVEMENTS FOR PROTAGONIST, HIGHLIGHTED BY THE U.S. APPROVAL OF ICOTYDE, FDA GRANTING PRIORITY REVIEW FOR RUSFERTIDE, AND ADVANCEMENT OF OUR HIGHLY DIFFERENTIATED AND FULLY-OWNED PEPTIDES PN-881 AND PN-477," SAID DINESH V.

PROTAGONIST REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

OPT-OUT ELECTION MAKES PROTAGONIST ELIGIBLE FOR $200 MILLION UPON EXERCISE AND AN ADDITIONAL $200 MILLION UPON FDA APPROVAL OF RUSFERTIDE FOR POLYCYTHEMIA VERA APPROVAL WOULD ALSO TRIGGER A $75 MILLION MILESTONE PAYMENT, BRINGING TOTAL POTENTIAL CASH TIED TO THE OPT-OUT ELECTION AND APPROVAL TO $475 MILLION PROTAGONIST BECOMES ELIGIBLE FOR UP TO $975 MILLION IN MILESTONE PAYMENTS AND TIERED ROYALTIES RANGING FROM 14% TO 29% ON WORLDWIDE NET SALES NEWARK, CA / ACCESS NEWSWIRE / APRIL 28, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT IT HAS EXERCISED ITS RIGHT TO OPT OUT OF THE 50:50 U.S. PROFIT AND LOSS SHARING ARRANGEMENT UNDER ITS WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH TAKEDA FOR RUSFERTIDE, AN INVESTIGATIONAL FIRST-IN-CLASS HEPCIDIN MIMETIC PEPTIDE UNDER U.S. FOOD AND DRUG ADMINISTRATION (FDA) PRIORITY REVIEW FOR THE TREATMENT OF ADULTS WITH POLYCYTHEMIA VERA (PV). BY EXERCISING ITS OPT-OUT RIGHT DURING THE CONTRACTUAL OPT-OUT PERIOD, PROTAGONIST BECOMES ELIGIBLE TO RECEIVE UP TO $400 MILLION IN OPT-OUT PAYMENTS, CONSISTING OF $200 MILLION PAYABLE UPON THE OPT-OUT ELECTION AND A FURTHER $200 MILLION PAYABLE UPON FDA APPROVAL OF RUSFERTIDE FOR THE TREATMENT OF ADULTS WITH PV.

PROTAGONIST EXERCISES RUSFERTIDE U.S. OPT-OUT RIGHT UNDER TAKEDA COLLABORATION

NEWARK, CA / ACCESS NEWSWIRE / APRIL 16, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON APRIL 15, 2026, IT ISSUED INDUCEMENT AWARDS TO TWO RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

PROTAGONIST THERAPEUTICS REPORTS GRANTING OF INDUCEMENT AWARDS

ONE-YEAR PHASE 3 DATA FOR ICOTYDE TO BE PRESENTED AT AAD 2026 DEMONSTRATE LASTING SKIN CLEARANCE AND A FAVORABLE SAFETY PROFILE IN A ONCE DAILY PILL FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS RESULTS FURTHER SUPPORT THE DIFFERENTIATED PROFILE OF ICOTYDE, THE FIRST AND ONLY IL-23 RECEPTOR TARGETED ORAL PEPTIDE NEWARK, CA / ACCESS NEWSWIRE / MARCH 28, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY ANNOUNCED NEW ONE-YEAR PHASE 3 RESULTS FOR ICOTYDE (ICOTROKINRA) WERE PRESENTED AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING. DATA FROM THE PHASE 3 ICONIC-ADVANCE 1 AND 2 AND ICONIC-LEAD STUDIES FURTHER SUPPORT THE POTENTIAL OF ICOTYDE AS A DIFFERENTIATED ORAL THERAPY FOR PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.

PROTAGONIST ANNOUNCES PRESENTATION OF ONE-YEAR PHASE 3 DATA FOR ICOTYDE(TM) IN MODERATE-TO-SEVERE PLAQUE PSORIASIS AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING

ICOTYDE IS THE FIRST AND ONLY IL-23R TARGETED ORAL PEPTIDE THAT DELIVERS COMPLETE SKIN CLEARANCE AND A FAVORABLE SAFETY PROFILE IN A ONCE-DAILY PILL APPROVAL SUPPORTED BY FOUR PHASE 3 STUDIES THAT MET ALL PRIMARY ENDPOINTS AND DEMONSTRATED A FAVORABLE SAFETY PROFILE IN 2,500 PATIENTS $50 MILLION MILESTONE PAYMENT TRIGGERED BY FDA APPROVAL; PROTAGONIST IS ELIGIBLE TO RECEIVE 6 - 10% ROYALTIES ON SALES AND UP TO $580 MILLION IN FUTURE MILESTONE PAYMENTS WEBCAST AND CONFERENCE CALL TO BE HELD AT 8:30 AM ET ON MARCH 18 NEWARK, CA / ACCESS NEWSWIRE / MARCH 18, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") ANNOUNCED TODAY THAT JOHNSON & JOHNSON RECEIVED U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR ICOTYDE (ICOTROKINRA), AN INTERLEUKIN-23 (IL-23) RECEPTOR ANTAGONIST FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WHO WEIGH AT LEAST 40 KG WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY. ICOTYDE IS THE FIRST AND ONLY TARGETED ORAL PEPTIDE THAT PRECISELY BLOCKS THE IL-23 RECEPTOR.

PROTAGONIST THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF ICOTYDE(TM) (ICOTROKINRA) FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

OSAKA, JAPAN & CAMBRIDGE, MASS. & NEWARK, CALIF.--(BUSINESS WIRE)--TAKEDA (TSE:4502/NYSE:TAK) AND PROTAGONIST THERAPEUTICS, INC. (PROTAGONIST) (NASDAQ:PTGX) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTED THE NEW DRUG APPLICATION (NDA) AND GRANTED PRIORITY REVIEW FOR RUSFERTIDE. RUSFERTIDE IS AN INVESTIGATIONAL, FIRST-IN-CLASS HEPCIDIN MIMETIC PEPTIDE THERAPEUTIC FOR THE TREATMENT OF ADULTS WITH POLYCYTHEMIA VERA (PV). THE FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT.

TAKEDA AND PROTAGONIST ANNOUNCE U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR RUSFERTIDE AS A POTENTIAL FIRST-IN-CLASS THERAPY FOR POLYCYTHEMIA VERA

(THIS RELEASE UPDATES THE RELEASE THAT POSTED EARLIER ON FEBRUARY 25, 2026 TO UPDATE THE SUB HEADLINES.) NDA FOR RUSFERTIDE SUBMITTED TO THE US FOOD AND DRUG ADMINISTRATION (FDA), WITH POTENTIAL APPROVAL AND LAUNCH THIS YEAR COMPANY EXPECTS TO OPT-OUT OF THE 50:50 PROFIT AND LOSS SHARING ARRANGEMENT FOR RUSFERTIDE WITH TAKEDA DURING A 90-DAY WINDOW EXPECTED TO OPEN IN Q2 U.S. REGULATORY DECISION FOR ICOTYDETM (ICOTROKINRA) ANTICIPATED IN 2026 WITH POTENTIAL LAUNCH THIS YEAR PN-881 PHASE 1 COMPLETION EXPECTED BY MID-2026 PRE-CLINICAL PIPELINE EXPANDED WITH NOVEL WHOLLY-OWNED CANDIDATES PN-477, AN ORAL AND S.C.

CORRECTION: PROTAGONIST REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NDA FOR RUSFERTIDE SUBMITTED TO THE US FOOD AND DRUG ADMINISTRATION (FDA), WITH POTENTIAL APPROVAL AND LAUNCH THIS YEAR COMPANY EXPECTS TO OPT-OUT OF THE 50:50 PROFIT AND LOSS SHARING ARRANGEMENT FOR RUSFERTIDE WITH TAKEDA DURING A 90-DAY WINDOW EXPECTED TO OPEN IN Q2 U.S. REGULATORY DECISION FOR ICOTYDETM (ICOTROKINRA) ANTICIPATED IN 2026 WITH POTENTIAL LAUNCH THIS YEAR PN-881 PHASE 1 COMPLETION EXPECTED BY MID-2026 NEWARK, CALIFORNIA / ACCESS NEWSWIRE / FEBRUARY 25, 2026 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025 AND PROVIDED A CORPORATE UPDATE. "IN 2025, PROTAGONIST REACHED NEW HEIGHTS WITH MULTIPLE SUCCESSFUL PHASE 3 OUTCOMES AND TWO NDA FILINGS OF OUR PARTNERED ASSETS, ICOTYDE AND RUSFERTIDE," SAID DINESH V.

PROTAGONIST REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEWARK, CA / ACCESS NEWSWIRE / FEBRUARY 24, 2026 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT DINESH V. PATEL, PH.D.

PROTAGONIST THERAPEUTICS TO PARTICIPATE IN MULTIPLE INVESTMENT BANK CONFERENCES IN MARCH 2026

NEWARK, CA / ACCESS NEWSWIRE / JANUARY 7, 2026 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT DINESH V. PATEL, PH.D.

Protagonist Therapeutics, Inc.

PTGX

Price

Financial Reports

No items found.

Press Releases

Protagonist Therapeutics, Inc.

PTGX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PTGX